Johnson & Johnson announced that its Board of Directors has elected CEO Joaquin Duato, to assume the additional position of Chairman, effective in January 2023. Duato succeeds Alex Gorsky, who will step down from his role as Executive Chairman following a brief transitional period. Duato has served as Johnson & Johnson’s CEO and a member of the Board of Directors since January 3, 2022. Prior to that time, he held senior leadership positions over his 30-plus year career with the company across multiple business sectors, geographics and functions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo
- AC Immune’s ACI-35.030 selected for further development
- Horizon Therapeutics jumps 33% after deal talks with Amgen, Janssen, Sanofi
- Horizon Therapeutics confirms preliminary deal talks with Amgen, Janssen, Sanofi
- Craig-Hallum sees potential for competing Apollo Endosurgery bids